scholarly journals Serum Anticholinergic Activity: A Possible Peripheral Marker of the Anticholinergic Burden in the Central Nervous System in Alzheimer’s Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Koji Hori ◽  
Kimiko Konishi ◽  
Masayuki Tani ◽  
Hiroi Tomioka ◽  
Ryo Akita ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Cholinergic System ◽  
Lewy Body Dementia ◽  
Compensatory Mechanisms ◽  
Anticholinergic Activity ◽  
The Central Nervous System ◽  
Anticholinergic Burden

We review the utility of serum anticholinergic activity (SAA) as a peripheral marker of anticholinergic activity (AA) in the central nervous system (CAA). We hypothesize that the compensatory mechanisms of the cholinergic system do not contribute to SAA if their system is intact and that if central cholinergic system deteriorates alone in conditions such as Alzheimer’s disease or Lewy body dementia, CAA and SAA are caused by way of hyperactivity of inflammatory system and SAA is a marker of the anticholinergic burden in CNS. Taking into account the diurnal variations in the plasma levels of corticosteroids, which are thought to affect SAA, it should be measured at noon or just afterward.

scholarly journals Functions of the Alzheimer’s Disease Protease BACE1 at the Synapse in the Central Nervous System

2016 ◽  
Vol 60 (3) ◽  
pp. 305-315 ◽  
Author(s):  
Kathryn M. Munro ◽  
Amelia Nash ◽  
Martina Pigoni ◽  
Stefan F. Lichtenthaler ◽  
Jenny M. Gunnersen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
The Central Nervous System

Nerve Growth Factor (NGF) in the Central Nervous System: Implications for the Treatment of Alzheimer’s Disease

Brain Repair ◽  
1990 ◽  
pp. 99-112
Author(s):  
Dan Lindholm ◽  
Christine Bandtlow ◽  
Matthias Spranger ◽  
Bastian Hengerer ◽  
Michael Meyer ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Nerve Growth ◽  
The Central Nervous System

scholarly journals CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Peiqing Chen ◽  
Wenjuan Zhao ◽  
Yanjie Guo ◽  
Juan Xu ◽  
Ming Yin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Early Diagnosis ◽  
Vital Role ◽  
Therapeutic Interventions ◽  
Chemokine Ligand ◽  
The Central Nervous System ◽  
Receptor Cx3cr1

CX3C chemokine ligand 1 (CX3CL1) is an intriguing chemokine belonging to the CX3C family. CX3CL1 is secreted by neurons and plays an important role in modulating glial activation in the central nervous system after binding to its sole receptor CX3CR1 which mainly is expressed on microglia. Emerging data highlights the beneficial potential of CX3CL1-CX3CR1 in the pathogenesis of Alzheimer’s disease (AD), a common progressive neurodegenerative disease, and in the progression of which neuroinflammation plays a vital role. Even so, the importance of CX3CL1/CX3CR1 in AD is still controversial and needs further clarification. In this review, we make an attempt to present a concise map of CX3CL1-CX3CR1 associated with AD to find biomarkers for early diagnosis or therapeutic interventions.

scholarly journals REVIEW ON ELECTROENCEPHALOGRAPHIC FINDINGS IN PATIENTS WITH ALZHEIMER'S DISEASE

2021 ◽  
Vol 27 (1) ◽  
pp. 3529-3533
Author(s):  
Ivan Todorov ◽  
◽  
Kosta Kostov ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Cognitive Impairment ◽  
Low Cost ◽  
The Elderly ◽  
Pathological Process ◽  
The Central Nervous System ◽  
Progressive Cognitive Impairment

Nowadays, with the constant enhancement of the longevity of the human population, the spreading of dementia is in steady rising. Among the many different sources of progressive cognitive impairment, Alzheimer's disease plays a major role being the most common reason for mental decline in the elderly population. Alzheimer's disease is a neurodegenerative disease of the central nervous system that leads to progressive cognitive impairment and has severe health, social and economic tolls. The lack of effective treatment and the problems of the daily living that the disease creates for the patients and their families raises many important issues in modern times. Due to the effect on the individuals and the need for a permanent caregiver, it is of high importance to have accessible tools for early diagnostic and assessment of the ongoing treatment. Electroencephalography is a noninvasive, easily reproductive diagnostic method with low cost that can be performed in different stages of the diseases of the central nervous system and give input on the current condition. This review presents the current achievements in the field of the usage of electroencephalography and its specific findings in patients with Alzheimer's disease and the qualitative and quantitative changes that appears and are important for early diagnosis, differential diagnostic, prediction of acceleration of the pathological process, distinguishing of co-existing conditions and follow-up of the effect of the administered treatment.

Sign in / Sign up

Export Citation Format

Share Document